Click here to watch the video version of this podcast.
“You can see and feel a buzz within the company right now,” said Andrew Stewart, President, Global Pharmaceuticals and International Consumer, at Bausch + Lomb.
Bausch + Lomb’s current momentum stems not only from new leadership, but also from recent collaborations, partnerships, and acquisitions.
Stewart and Yehia Hashad, MD, Executive Vice President of Research & Development and Chief Medical Officer, join host Paul Karpecki, OD, to discuss these activities. Miebo, the first-in-class dry eye asset for the treatment of evaporative dry eye, tops the list.
Looking ahead, Stewart and Dr. Hashad said the company is lasering its focus to tackle more unmet medical needs in eye care. The company intends to build on its legacy of innovation in drug delivery, in MOAs, and in developing new molecular entities.
What’s next for the most recognized name in eye care?
Topics discussed include:
• Why Stewart shifted into commercial from R&D, and why Dr. Hashad moved from clinical practice to R&D.
• How Bausch + Lomb leadership is looking at the future for a company with a 170-year legacy.
• Bausch + Lomb’s holistic approach to dry eye disease and treatment.
• The company’s thinking behind acquiring the rights from Novaliq to pursue development of what is now Miebo.
• The importance of addressing unmet needs with respect to the Bausch pipeline.
• What excites Dr. Hashad and Stewart about the company right now.
• Where they would like to see Bausch + Lomb in the next three to five years, including for Miebo, for ocular surface disease treatments, and for eye care.
Andrew Stewart https://www.bausch.com/about-bausch-lomb/leadership-team
Yehia Hashad, MD https://www.bausch.com/about-bausch-lomb/leadership-team
Paul Karpecki, OD https://ois.net/paul-karpecki-od